FDAは乳がんの進行を承認し 化学療法よりも37% 良い結果を出す FDA approves Datroway for advanced breast cancer, offering a 37% better outcome than chemo.

FDAは,前もって内分泌基質および化学療法を受けた,進行中のホルモン受容体陽性,HER2陰性乳がんの成人患者に対する新しい治療法であるDatrowayを承認しました. The FDA has approved Datroway, a new treatment for certain adult patients with advanced hormone receptor-positive, HER2-negative breast cancer who have previously received endocrine-based and chemotherapy treatments. TROPON-BENT01の裁判によると,ダトロウェイは標準化学療法に比べて,病気の進行又は死亡のリスクを37%減少し,口痛,吐き気、疲労など共通の副作用が生じている. According to the TROPION-Breast01 trial, Datroway reduces the risk of disease progression or death by 37% compared to standard chemotherapy, with common side effects including mouth sores, nausea, and fatigue. この薬は1瓶当たり4,891.07ドルで,米国では2週間以内に患者さんに提供される予定です. The drug is priced at $4,891.07 per vial and is expected to be available to U.S. patients in two weeks.